APNHY:OTC-Aspen Pharmacare Holdings Limited (USD)

COMMON STOCK | Drug Manufacturers-Specialty & Generic | OTC

Last Closing Price

USD 16.35

Change

-0.15 (-0.91)%

Market Cap

USD 7.62B

Volume

235.00

Avg Analyst Target

N/A

Avg User Target

USD
Average Analyst Rating

N/A

Fundamental Analysis

Verdict

About

Aspen Pharmacare Holdings Limited, together with its subsidiaries, manufactures and supplies specialty and branded pharmaceutical products worldwide. It operates in Commercial Pharmaceuticals and Manufacturing segments. The company provides general anesthetics, muscle relaxants, and topical agents under the Anaesthetics brand; and a range of injectable anticoagulants with a focus on low molecular weight heparins, Xa inhibitors, and heparin derivatives under the Thrombosis brand. It also offers branded consumer, prescription, and over-the-counter products under the regional brands, such as Circadin, Foxair, Maltofer, Mybulen, and Zyloric for various types of anesthetic comprises sleeping aid, respiratory, iron supplement, analgesic, and uric acid production inhibitor.in addition, the company manufactures and sells active pharmaceutical ingredients and finished dose form products to third-party customers. The company was founded in 1850 and is headquartered in Durban, South Africa.

Company Website : http://www.aspenpharma.com

Address : Aspen Place, Durban, South Africa

Employees : 8,581

Fiscal Year End : June

Currency: USD

Country : USA

Technical Indicators

Beta : 0.57

52 Week High : 18.79

52 Week Low : 6.42

200 Day Moving Average : 12.88

50 Day Moving Average : 16.36

Shares Held by Institutions : 0%

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-10-27 )

Largest Industry Peers for Drug Manufacturers-Specialty & Generic

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MKGAF MERCK Kommanditgesellschaft au..

-2.67 (-1.13%)

 USD102.33B 32.30 20.03
MKKGY MERCK Kommanditgesellschaft au..

-0.09 (-0.19%)

 USD102.28B 32.21 20.03
TKPHF Takeda Pharmaceutical Company ..

+0.41 (+1.48%)

 USD43.55B 11.50 0.07
ESALY Eisai Co. Ltd

+0.07 (+0.09%)

 USD20.40B 38.75 0.17
ESALF Eisai Co. Ltd

N/A

 USD20.12B 38.24 0.17
SGIOF Shionogi & Co. Ltd

-0.30 (-0.46%)

 USD19.87B 18.70 0.11
SGIOY Shionogi & Co. Ltd

-0.10 (-0.61%)

 USD19.70B 18.55 0.11
SFOSF Shanghai Fosun Pharmaceutical ..

-0.35 (-7.06%)

 USD19.40B 18.67 2.49
TEVJF Teva Pharmaceutical Industries..

N/A

 USD11.31B 900.00 16.02
MTZPY Mitsubishi Tanabe Pharma Corpo..

N/A

 USD10.43B 79.00 0.21

ETFs Containing APNHY

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers-Specialty & Generic)		 Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 93.26% 84% B 83% B
Dividend Return 2.16% 63% D 34% F
Total Return 95.42% 84% B 83% B
Trailing 12 Months  
Capital Gain 144.03% 81% B- 83% B
Dividend Return 2.73% 67% D+ 34% F
Total Return 146.76% 80% B- 83% B
Trailing 5 Years  
Capital Gain -23.60% 48% F 35% F
Dividend Return 2.29% 25% F 6% F
Total Return -21.31% 49% F 35% F
Average Annual (5 Year Horizon)  
Capital Gain -4.00% 31% F 18% F
Dividend Return 0.41% 19% F 15% F
Total Return -3.59% 30% F 17% F
Risk Return Profile  
Volatility (Standard Deviation) 47.62% 72% C- 51% F
Risk Adjusted Return -7.53% 30% F 19% F
Market Capitalization 7.62B 94% A 85% B
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers-Specialty & Generic)		 Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 23.24 28% F 32% F
Price/Book Ratio 1.64 57% F 52% F
Price / Cash Flow Ratio 1.12 21% F 39% F
EV/EBITDA 1.31 68% D+ 64% D
Management Effectiveness  
Return on Equity 7.12% 77% C+ 55% F
Return on Invested Capital -2.15% 55% F 36% F
Return on Assets 4.28% 83% B 77% C+
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio N/A N/A N/A N/A N/A
Short Percent N/A N/A N/A N/A N/A
Beta 0.57 64% D 64% D
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters then its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.